Bottom line
FBT vs BIB: the short answer
FBT (First Trust NYSE Arca Biotechnology Index Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are both etfs.
But BIB is far broader, holding 267 positions to 32 for FBT, so beyond the top names it adds exposure FBT doesn't have.
FBT is cheaper at 0.55% vs 0.95% — a difference of $40 a year per $10,000 invested.
Over five years, FBT returned +4.3% a year vs −1.0% for BIB.
Updated Nov 19, 2026
FBT vs BIB side by side
| FBT | BIB | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | First Trust | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.55% | 0.95% |
| Annual cost per $10k | $55 | $95 |
| 10-yr cost on $10k (prospectus) | — | $1,401 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +24.1% | +59.3% |
| 5-yr return (annualized) | +4.3% | −1.0% |
| 10-yr return (annualized) | +6.3% | +1.4% |
| Best quarter | +27.8% | +56.2% |
| Worst quarter | −22.5% | −42.7% |
| Net assets (fund) | $2.8B | $73.7M |
| Number of holdings | 32 | 267 |
| Portfolio turnover | 37% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBT | BIB | Difference |
|---|---|---|---|
| 2025 | +24.1% | +59.3% | −35.3% |
| 2024 | +5.8% | −10.0% | +15.8% |
| 2023 | +2.3% | −1.3% | +3.5% |
| 2022 | −4.6% | −28.6% | +24.0% |
| 2021 | −3.6% | −5.9% | +2.3% |
| 2020 | +12.9% | +39.7% | −26.8% |
| 2019 | +19.8% | +45.5% | −25.7% |
| 2018 | −0.2% | −24.4% | +24.2% |
| 2017 | +37.0% | +40.8% | −3.8% |
| 2016 | −19.6% | −44.2% | +24.6% |
Source: Fund prospectus bar charts
Holdings overlap
8 of FBT's top 25 holdings also appear in BIB's top 25.
| Holding | FBT | BIB |
|---|---|---|
| Illumina Inc | 3.92% | 1.25% |
| Biogen Inc | 3.37% | 1.44% |
| Incyte Corp | 3.18% | 0.97% |
| Argenx Se | 3.13% | 1.19% |
| Vertex Pharmaceuticals Inc | 3.07% | 4.65% |
| Amgen Inc | 2.78% | 4.48% |
| United Therapeutics Corp | 2.56% | 1.22% |
| Alnylam Pharmaceuticals Inc | 2.52% | 2.01% |
Source: SEC Form N-PORT
FBT top 10
- Corcept Therapeutics Inc — 5.60%
- Neogenomics Inc — 5.12%
- Veracyte Inc — 5.10%
- Bruker Corp — 4.32%
- Alkermes Plc — 4.24%
- Illumina Inc — 3.92%
- Krystal Biotech Inc — 3.87%
- Natera Inc — 3.79%
- Axsome Therapeutics Inc — 3.71%
- Neurocrine Biosciences Inc — 3.53%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between FBT and BIB?
Which is cheaper, FBT or BIB?
Should I own both FBT and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.